Company news

Alterity Therapeutics Ltd. (ASX:ATH) news

Alterity Therapeutics Ltd. news releases on 6ix. Latest, Oct 5, 2026: Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System…

Alterity Therapeutics Ltd. (ASX:ATH) news

Press releases & updates

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026

$4.2M Options Underwriting Agreement Executed

Appendix 4E and 2026 Annual Report

Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434

Granted New U.S. Composition of Matter Patent for ATH434

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update

Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026

ATH Receives A$3.98m R&D Tax Incentive

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

FDA Meeting Minutes Confirm Registrational Path for ATH434

Alterity Therapeutics : Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

Alterity Therapeutics : Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

Notice of General Meeting/Proxy Form

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

Alterity Receives Positive FDA Feedback on CMC Meeting

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

Alterity Receives Positive FDA Feedback From Type C Meeting

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Half Yearly Report and Accounts

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Quarterly Activities/Appendix 4C Cash Flow Report

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

Alterity Board Changes

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System

Alterity Therapeutics : Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSAat the 36th International Symposium on the Autonomic Nervous System

Alterity Therapeutics : Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

Alterity Therapeutics : Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

Alterity Therapeutics : Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Alterity Raises A$20.0 million in Strategic Placement

Alterity Therapeutics : Raises A$20.0 million in Strategic Placement

Trading Halt

Alterity Therapeutics to Present at the Biotech Showcase

Appendix 4E and 2025 Annual Report

Response to ASX Query Letters